Wart News and Research

RSS

A wart is a raised growth on the surface of the skin or other organ.

Graceway receives FDA approval for Zyclara Cream to treat genital warts

Graceway Pharmaceuticals announced today that the Food and Drug Administration has approved Zyclara Cream for the treatment of external genital and perianal warts in patients 12 years of age and older.

25 Mar 2011

Prestige Brands third quarter revenues increase 22.7% to $90.6 million

Prestige Brands Holdings, Inc. today announced results for the third quarter and nine months of fiscal year 2011, which ended on December 31, 2010. Following the close of the quarter, the Company completed the previously announced acquisition of the Dramamine® Brand in the U.S. from McNeil-PPC, Inc.

9 Feb 2011

HPV vaccine can prevent 90% of genital warts in men: Study

The vaccine for human papillomavirus can prevent 90 percent of genital warts in men when offered before exposure to the four HPV strains covered by the vaccine, according to a new multi-center study led by H. Lee Moffitt Cancer Center and UCSF.

4 Feb 2011

Time constraints, patient embarrassment prevent full-body skin cancer examinations

Time constraints, other illnesses and patient embarrassment may prevent dermatologists, internists and family practitioners from conducting full-body skin examinations, according to a report in the January issue of Archives of Dermatology, one of the JAMA/Archives journals. However, dermatologists are significantly more likely than internists and family practitioners to conduct such screenings.

18 Jan 2011

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds showed excellent in vitro antiviral activity and no cellular toxicity at dose levels tested for Human Papillomavirus (HPV).

30 Nov 2010

Prestige Brands second fiscal quarter net revenue decreases 3% to $78.3 million

Prestige Brands Holdings, Inc. today announced results for the second quarter and first half of fiscal year 2011, which ended on September 30, 2010. The Company also announced the completion on November 1, 2010 of the acquisition of Blacksmith Brands, Inc., which added five over-the-counter healthcare products to its business.

4 Nov 2010

Prestige Brands agrees to acquire Blacksmith Brands stock for $190 million

Prestige Brands Holdings, Inc., a leading marketer of branded consumer products, today announced that it has entered into a definitive agreement to acquire 100% of the stock of Blacksmith Brands Holdings, Inc., for $190 million in cash.

20 Sep 2010

Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference

Results from a Phase III program evaluating imiquimod 3.75% and 2.5% creams for the treatment of EGW, applied once daily for up to 8 weeks, demonstrated that both were well-tolerated and more efficacious than placebo, according to data presented at the annual Human Papillomavirus Conference in Montreal, July 3 - 8. Investigators found that efficacy was greatest for imiquimod 3.75% with an enhanced safety profile.

9 Jul 2010

Mass vaccination has reduced the incidence of genital warts by 60%: Report

Genital warts, commonly caused by human papillomavirus (HPV) are on the decline after routine vaccination of Australian women with a vaccine against HPV. The sexual partners of these women are also beneficiaries of the vaccine.

5 Jul 2010

Metabolex, Sanofi-Aventis sign global license deal to develop GPR119 for type 2 diabetes treatment

Metabolex and Sanofi-Aventis announced today that they have entered into a global license and development agreement for the research, development, manufacture and commercialization of small molecules that modulate the G-protein coupled receptor 119 (GPR119), a receptor in the gut and pancreas that interacts with bioactive lipids to stimulate glucose-dependent incretin and insulin secretion.

30 Jun 2010

Metabolex signs global development and license agreement with OMJPI

Metabolex, Inc. announced today that they have entered into a global development and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. to further develop and discover compounds for the treatment of type 2 diabetes and other disorders. Under the agreement, OMJPI will receive an exclusive worldwide license to develop, manufacture, and commercialize several Metabolex programs that are currently at the preclinical stage.

22 Jun 2010

Prestige Brands Holdings fourth fiscal quarter revenues up 4% to $71.4 million

Prestige Brands Holdings, Inc. today reported results for the fourth fiscal quarter and fiscal year ended March 31, 2010.

13 May 2010

Prestige Brands provides update on 9 ¼% Senior Subordinated Notes due 2012 tender offer

Prestige Brands Holdings, Inc. previously announced that, on March 10, 2010, its wholly-owned subsidiary Prestige Brands, Inc. commenced a cash tender offer for any and all of its 9 ¼% Senior Subordinated Notes due 2012, of which $126 million aggregate principal amount were outstanding at that time.

7 Apr 2010

Work addiction is a psychosocial problem

Researchers from the Jaume I University have proven the usefulness of DUWAS, a new scale for measuring addiction to work, a disorder that affects around 12% of all working people in Spain.

26 Mar 2010

In addition to anal and cervical cancer, HPV can also cause head and neck cancer

The Human Papillomavirus (HPV) is the causative agent responsible for most cases of cervical cancer, but is also associated with several other types of cancer.

12 Mar 2010

UTSA celebrates grand opening of NVI facility in the greater San Antonio region

The University of Texas at San Antonio celebrates the grand opening of its New Venture Incubator, a facility with laboratory, office and meeting spaces to support technology start-ups in the greater San Antonio region. The incubator, housed on UTSA’s Main Campus, will serve as a bridge between San Antonio entrepreneurs and the region’s research and development community.

8 Mar 2010

Prestige Brands Holdings announces results for third fiscal quarter ended December 31, 2009

Prestige Brands Holdings, Inc. today announced results for the third fiscal quarter and nine months ending December 31, 2009.

5 Feb 2010

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine.

11 Nov 2009

Positive results from Metabolex' Phase 1 MBX-2982 clinical trial for treating type 2 diabetes

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from two multiple ascending dose Phase 1 clinical trials of MBX-2982.

14 Oct 2009

CDC to review vaccine policies; immigrant, women's rights advocates anticipating repeal of HPV vaccine requirement

A coalition of more than 100 groups representing women, immigrants, and public health and reproductive rights advocates are hoping CDC will repeal its rule requiring female immigrants seeking U.S. citizenship to receive the human papillomavirus vaccine Gardasil, the AP/Newark Star-Ledger reports (Garay, AP/Newark Star-Ledger, 5/7).

12 May 2009